Standard therapy of human visceral leishmaniasis with parenteral pentavalent antimonial agents is generally curative but has the disadvantages of a 28-day treatment course, occasional treatment failures, and toxicity.
amphotericin B. These experiments suggest that ABCD is at least four times as active as conventional amphotericin B against visceral leishmaniasis and that clinical trials are warranted.
Leishmaniasis results from infection with protozoal parasites of the genus Leishmania. Insect-transmitted forms of leishmaniae are inoculated into the skin via the bite of a female sandfly. The insect-transmitted forms cannot survive long in a mammalian host: within a few hours, the only parasites to be seen are within mononuclear phagocytes. Throughout the rest of the interaction between the parasite and its human host, leishmaniae are obligate intramacrophage microorganisms. Visceral leishmaniasis results from infection of the macrophages of the liver, spleen, and bone marrow with leishmaniae. The symptoms of established disease are fever, weight loss, hepatosplenomegaly, and pancytopenia. If untreated, established disease is characteristically fatal because of intercurrent infections such as diarrhea and pneumonia.
The first antileishmanial chemotherapeutic agents with a favorable therapeutic index, the pentavalent antimonial agents (Sb), were introduced in the 1940s and are still the primary therapy for all forms of leishmaniasis. The formulations available then and now are sodium stibogluconate (Pentostam), in which Sb is reacted with gluconic acid to form an unknown number of compounds of unknown structure (3), and meglumine antimonate (Glucantime), in which pentavalent antimony is reacted with the sugar meglumine to form a similarly unknown set of products. Although Sb will heal approximately 90% of patients with visceral disease (10) (1) . In preparation for clinical testing of ABCD against human kala-azar, we determined the relative efficacies of ABCD and conventional amphotericin B in viscerally infected hamsters. 
MATERIALS AND METHODS
Hamster experiments. Hamsters were infected with Leishmania donovani (WR# 378) and administered with drugs exactly as described previously (4, 8) . In brief, 60-to 80-g hamsters (Mesocricetus auratus) were administered intracardiac injections of approximately 107 L. donovani amastigotes (Khartoum strain). Three days later (lightly infected animals) or 10 days later (heavily infected animals), the six to eight animals in each group were administered with 5% dextrose in water (negative controls), conventional amphotericin B, ABCD, or meglumine antimonate (positive controls). All preparations were administered via intracardiac injection in less than 1 min, except for meglumine antimonate, which was given intramuscularly. The animals were sacrificed 2 to 14 days after the single injection of the drug, and the number of parasites per liver was determined from the ratio of parasites per liver cell nucleus and from the weight of the liver, as previously described (8) .
Computations. For each experimental group, the mean number of parasites per liver was determined from the values for the individual animals, and percent parasite suppression was calculated as follows: [(mean number of parasites in negative controls) - Table 2 . This second experiment was designed to investigate whether the relative activity of ABCD versus conventional amphotericin B was maintained in heavily infected hamsters and to investigate the length of time that either formulation would be active after one administration. Thus, the animals were allowed to become more heavily infected prior to drug administration, and the animals were sacrificed at different intervals after dosing.
In animals administered with dextrose and sacrificed 2 days later (12 days after infection with parasites), there were more organisms (1.7 x 109 per liver) than in the lightly infected animals in experiment 1 (4) or when amphotericin B in the form of distearoylphosphatidylglycerol was used in a mouse model (5), the experiments were performed at different times or in different models and the results are noncomparable.
The improvement in hepatic antileishmanial efficacy of ABCD demonstrated here is consistent with the increased removal of ABCD, compared with conventional amphotericin B, from the circulation by the liver and bone marrow. In preclinical work, dogs were administered with 0.6 mg of ABCD or conventional amphotericin B per kg. Levels of ABCD in plasma were one-fifth the levels of amphotericin B desoxycholate, levels of ABCD in liver and bone marrow were 1.7 to 2.7 times higher than those of amphotericin B desoxycholate, and levels of ABCD in kidneys were oneseventh the levels of amphotericin B desoxycholate (7) .
The hamster efficacy experiments and the dog drug distribution data suggest that ABCD should be two to four times more effective than conventional amphotericin B against visceral leishmaniasis. The drug distribution study also suggests that ABCD should be less toxic to kidneys than conventional amphotericin B. If these suggestions hold for the clinical situation, the total amount of amphotericin B normally administered to patients with leishmaniasis could be cut at least in half, and the drug could be given in relatively large daily doses. The relatively slight increase in antileishmanial activity between 2 and 7 days after drug administration suggests that the dosing interval should be closer to 2 days than to 7 days. The amount of conventional amphotericin B normally required to cure human visceral leishmaniasis is not well investigated but is probably not more than 30 mg/kg. Davidson (6) . Clinical trials of higher daily doses of ABCD administered over a shorter period of time are now in progress.
